This study is checking if a combination of two drugs, nivolumab and ipilimumab, works better than nivolumab alone to shrink tumors in a type of endometrial cancer called **dMMR** recurrent endometrial carcinoma. **dMMR** stands for "deficient mismatch repair," which means the body's system for fixing damaged DNA isn't working well. **Nivolumab** and **ipilimumab** are **monoclonal antibodies** that can help the immune system fight cancer.

• The study involves regular visits for treatment every 3-4 weeks.
• Participants may need to provide tissue and blood samples, and undergo CT or MRI scans.
• There is follow-up every 3 months for 2 years, then every 6 months for 3 more years.

If you have this specific type of cancer, meet the eligibility criteria, and are interested in participating, the study could provide access to new treatment options. Participants will be monitored closely and must be willing to follow the treatment and sampling schedule. Additionally, women who can have children must agree to use birth control during the study. Always discuss with your doctor to understand the potential risks and benefits before deciding to join.